Compare NTRA & STZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | STZ |
|---|---|---|
| Founded | 2003 | 1945 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 24.8B |
| IPO Year | 2015 | 1987 |
| Metric | NTRA | STZ |
|---|---|---|
| Price | $229.36 | $137.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 19 |
| Target Price | ★ $238.20 | $173.21 |
| AVG Volume (30 Days) | 1.2M | ★ 2.5M |
| Earning Date | 11-06-2025 | 01-07-2026 |
| Dividend Yield | N/A | ★ 2.91% |
| EPS Growth | N/A | ★ 116.70 |
| EPS | N/A | ★ 6.84 |
| Revenue | $2,116,676,000.00 | ★ $9,624,000,000.00 |
| Revenue This Year | $33.18 | N/A |
| Revenue Next Year | $16.81 | $0.32 |
| P/E Ratio | ★ N/A | $20.48 |
| Revenue Growth | ★ 38.17 | N/A |
| 52 Week Low | $125.38 | $126.45 |
| 52 Week High | $246.90 | $228.89 |
| Indicator | NTRA | STZ |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 47.38 |
| Support Level | $227.89 | $137.41 |
| Resistance Level | $237.04 | $142.92 |
| Average True Range (ATR) | 5.07 | 3.56 |
| MACD | -1.57 | -0.62 |
| Stochastic Oscillator | 49.47 | 21.01 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Constellation Brands is the largest provider of alcoholic beverages across the beer, wine, and spirits categories in the US, generating 84% of revenue from Mexican beer imports under top-selling brands such as Modelo and Corona. The rest of the business includes some remaining wine and spirits brands, categories where the company has pruned assets in recent years. With its exclusive rights tied to the Mexican beer brands, effective only in the US, the firm has limited revenue exposure to international markets. Constellation owns a 26% stake in no-moat Canopy Growth, a medicinal and recreational cannabis producer in Canada, and has a 50/50 joint venture with glass manufacturer Owens-Illinois in Mexico.